Rosemont Pharmaceuticals occupies an unusual niche: founded in 1967, it makes oral medicines for patients – mostly old people – who have trouble swallowing standard pills and capsules. In 2006, UK-based lower mid-market group CBPE Capital paid £93 million to buy the business from former owner Savient Pharmaceuticals.
1. Sticking to the knitting
The first key decision, according to Dinnen, was to remain focused on liquids, rather than branching out into other related areas (like creams, ointments and so on). “Our fundamental strategy was to develop a business that had a reputation for being best-in-class globally in oral liquid formulations. Another owner could have gone down a different route, but we wanted to remain pure-play liquids.”